Vivos INC 10-Q quarterly reports

Vivos Inc. reports progress on FDA approvals for its RadioGel therapy and growth in its IsoPet animal division, but continues to face significant net losses and concerns about its going concern status.

Vivos Inc. reports increased revenue and strategic advancements in its precision radionuclide therapy for both human and animal oncology, alongside ongoing financing efforts.

Vivos Inc. reported increased net losses and cash burn in Q3 2025, while advancing strategic initiatives in human and animal therapies and facing FDA regulatory hurdles.

Vivos Inc. reported a wider net loss in Q2 2025 due to increased operating expenses and R&D, despite a rise in revenue, as it continues to fund its Y-90 therapy development and global expansion.

Vivos Inc. reports increased revenue for Q1 2025, driven by IsoPet therapies and clinic certifications, but continues to face significant net losses and going concern uncertainties.

Vivos Inc. reported its financial results for the third quarter of 2024, highlighting ongoing efforts in the development of its RadioGel technology and its application in both animal and human therapies.

Vivos Inc. reports a net loss of $1.06 million for the six months ended June 30, 2024, while continuing to develop its RadioGel technology and seeking additional funding.

Vivos Inc. reported a net loss of $558,539 for the first quarter of 2024, while continuing to advance its IsoPet veterinary therapy and pursue regulatory approvals for its RadioGel human therapy.